The magnitude of benefit of immune checkpoint inhibitors on overall survival for patients with advanced cancers is sex-dependent.
Compared to testing for BRCA1/2 mutations only, testing for multiple breast cancer-associated genes improves detection of pathogenic variants.
The FDA released information about decreased survival rates associated with the use of two different drugs.
A 60-year-old woman presented with a persistent dry cough, extreme fatigue, and a decrease in appetite following a diagnosis of streptococcal…
Treating early stage breast cancer patients for just six months with trastuzumab works as well as the current 12-month regimen.
New Version of the Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis
Ayalew Tefferi, MD, talks about the revised MIPSS version 2.0 and what it means for the future of primary myelofibrosis.
Three-month post-radiotherapy prostate specific antigen levels may be a strong prognostic biomarker for treatment response in patients with…